[Ambroxol].
Akkoca Yildiz
Oznur
O
Ankara Universitesi Tip Fakültesi Göğüs Hastaliklari Anabilim Dali, Ankara, Türkiye.
D000551:Ambroxol / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D016535:Bronchial Hyperreactivity / Q000188:drug therapy; D003550:Cystic Fibrosis / Q000188:drug therapy; D005100:Expectorants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D017136:Ion Transport / Q000187:drug effects; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D008171:Lung Diseases / Q000188:drug therapy*; D009079:Mucociliary Clearance / Q000187:drug effects; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000188:drug therapy; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D005100:Expectorants; D011663:Pulmonary Surfactants; D000551:Ambroxol